The FDA declined to approve one of biotech's most closely watched cancer drugs来源:Market Watch发布于 2026-11-16The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.相关标的:SMMT继续访问返回新闻本文内容来自外部来源,点击「继续访问」将跳转到原始发布站点。